Health insurance company Clover Health (NASDAQ:CLOV) will be announcing earnings results this Tuesday after market close. Here’s what to look for.
Clover Health missed analysts’ revenue expectations by 1.4% last quarter, reporting revenues of $462.3 million, up 33.3% year on year. It was a very strong quarter for the company, with an impressive beat of analysts’ EPS estimates and full-year EBITDA guidance exceeding analysts’ expectations. It added 20,754 customers to reach a total of 103,418.
Is Clover Health a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Clover Health’s revenue to grow 31.8% year on year to $469.5 million, improving from the 11.3% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.03 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Clover Health has missed Wall Street’s revenue estimates six times over the last two years.
Looking at Clover Health’s peers in the health insurance providers segment, some have already reported their Q2 results, giving us a hint as to what we can expect. CVS Health delivered year-on-year revenue growth of 8.4%, beating analysts’ expectations by 5.1%, and Alignment Healthcare reported revenues up 49%, topping estimates by 5.7%. CVS Health’s stock price was unchanged after the resultswhile Alignment Healthcare was up 5.7%.
Read our full analysis of CVS Health’s results here and Alignment Healthcare’s results here.
Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the health insurance providers stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Clover Health is down 4.1% during the same time and is heading into earnings with an average analyst price target of $4.69 (compared to the current share price of $2.77).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.